Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Preterm Children Have Higher Risk Than Full-term Children of Invasive Pneumococcal Disease During the First 2 Years of Life.

Riise ØR, Laake I, Vestrheim D, Winje BA, Moster D, Storsæter J.

Pediatr Infect Dis J. 2018 Jul;37(7):e195-e200. doi: 10.1097/INF.0000000000001989.

PMID:
29570592
2.

Impact on affected families and society of severe rotavirus infections in Swedish children assessed in a prospective cohort study.

Tran AN, Husberg M, Bennet R, Brytting M, Carlsson P, Eriksson M, Storsaeter J, Österlin B, Johansen K.

Infect Dis (Lond). 2018 May;50(5):361-371. doi: 10.1080/23744235.2017.1416162. Epub 2017 Dec 20.

PMID:
29260605
3.

Vaccination and allergy: EAACI position paper, practical aspects.

Nilsson L, Brockow K, Alm J, Cardona V, Caubet JC, Gomes E, Jenmalm MC, Lau S, Netterlid E, Schwarze J, Sheikh A, Storsaeter J, Skevaki C, Terreehorst I, Zanoni G.

Pediatr Allergy Immunol. 2017 Nov;28(7):628-640. doi: 10.1111/pai.12762. Epub 2017 Oct 10. Review.

4.

Risk of Pertussis in Relation to Degree of Prematurity in Children Less Than 2 Years of Age.

Riise ØR, Laake I, Vestrheim D, Flem E, Moster D, Riise Bergsaker MA, Storsæter J.

Pediatr Infect Dis J. 2017 May;36(5):e151-e156. doi: 10.1097/INF.0000000000001545.

PMID:
28403056
5.

Ecologic Study of Meningococcal B Vaccine and Neisseria gonorrhoeae Infection, Norway.

Whelan J, Kløvstad H, Haugen IL, Holle MR, Storsaeter J.

Emerg Infect Dis. 2016 Jun;22(6):1137-9. doi: 10.3201/eid2206.151093. No abstract available.

6.

Monitoring of timely and delayed vaccinations: a nation-wide registry-based study of Norwegian children aged < 2 years.

Riise ØR, Laake I, Bergsaker MA, Nøkleby H, Haugen IL, Storsæter J.

BMC Pediatr. 2015 Nov 13;15:180. doi: 10.1186/s12887-015-0487-4.

7.

Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012.

Zeddeman A, van Gent M, Heuvelman CJ, van der Heide HG, Bart MJ, Advani A, Hallander HO, Wirsing von Konig CH, Riffelman M, Storsaeter J, Vestrheim DF, Dalby T, Krogfelt KA, Fry NK, Barkoff AM, Mertsola J, He Q, Mooi F.

Euro Surveill. 2014 Aug 21;19(33). pii: 20881.

8.

A review of the evidence to inform pneumococcal vaccine recommendations for risk groups aged 2 years and older.

Steens A, Vestrheim DF, Aaberge IS, Wiklund BS, Storsaeter J, Riise Bergsaker MA, Rønning K, Furuseth E.

Epidemiol Infect. 2014 Dec;142(12):2471-82. doi: 10.1017/S0950268814001514. Epub 2014 Jun 16. Review.

PMID:
24932959
9.

Burden of severe rotavirus disease leading to hospitalization assessed in a prospective cohort study in Sweden.

Rinder M, Tran AN, Bennet R, Brytting M, Cassel T, Eriksson M, Frithiof D, Gothefors L, Storsaeter J, Trollfors B, Valdimarsson S, Wennerström M, Johansen K.

Scand J Infect Dis. 2014 Apr;46(4):294-302. doi: 10.3109/00365548.2013.876511. Epub 2014 Feb 3.

PMID:
24484415
10.

Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe.

Romio S, Weibel D, Dieleman JP, Olberg HK, de Vries CS, Sammon C, Andrews N, Svanström H, Mølgaard-Nielsen D, Hviid A, Lapeyre-Mestre M, Sommet A, Saussier C, Castot A, Heijbel H, Arnheim-Dahlström L, Sparen P, Mosseveld M, Schuemie M, van der Maas N, Jacobs BC, Leino T, Kilpi T, Storsaeter J, Johansen K, Kramarz P, Bonhoeffer J, Sturkenboom MC.

PLoS One. 2014 Jan 3;9(1):e82222. doi: 10.1371/journal.pone.0082222. eCollection 2014.

11.

Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A.

Heier MS, Gautvik KM, Wannag E, Bronder KH, Midtlyng E, Kamaleri Y, Storsaeter J.

Sleep Med. 2013 Sep;14(9):867-71. doi: 10.1016/j.sleep.2013.03.020. Epub 2013 Jun 14.

PMID:
23773727
12.

International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines.

Dodd CN, Romio SA, Black S, Vellozzi C, Andrews N, Sturkenboom M, Zuber P, Hua W, Bonhoeffer J, Buttery J, Crawford N, Deceuninck G, de Vries C, De Wals P, Gutierrez-Gimeno MV, Heijbel H, Hughes H, Hur K, Hviid A, Kelman J, Kilpi T, Chuang SK, Macartney K, Rett M, Lopez-Callada VR, Salmon D, Gimenez-Sanchez F, Sanz N, Silverman B, Storsaeter J, Thirugnanam U, van der Maas N, Yih K, Zhang T, Izurieta H; Global H1N1 GBS Consortium.

Vaccine. 2013 Sep 13;31(40):4448-58. doi: 10.1016/j.vaccine.2013.06.032. Epub 2013 Jun 14.

PMID:
23770307
13.

Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine.

Lavine JS, Bjørnstad ON, de Blasio BF, Storsaeter J.

Vaccine. 2012 Jan 11;30(3):544-51. doi: 10.1016/j.vaccine.2011.11.065. Epub 2011 Nov 26.

14.

Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis.

Cherry JD, Heininger U, Richards DM, Storsaeter J, Gustafsson L, Ljungman M, Hallander HO.

Clin Vaccine Immunol. 2010 May;17(5):741-7. doi: 10.1128/CVI.00469-09. Epub 2010 Mar 24.

15.

[Good immune response of diphtheria-tetanus-pertussis vaccination in the 4th grade. Local reaction very common--and expected].

Nilsson L, Carlsson RM, Hallander HO, Ljungman M, Hallberg M, Storsaeter J.

Lakartidningen. 2009 Sep 16-22;106(38):2357-61. Swedish. No abstract available.

PMID:
19848341
16.

Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children.

Hallander HO, Ljungman M, Storsaeter J, Gustafsson L.

APMIS. 2009 Nov;117(11):797-807. doi: 10.1111/j.1600-0463.2009.02530.x.

PMID:
19845530
17.

Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection.

Hallander HO, Ljungman M, Jahnmatz M, Storsaeter J, Nilsson L, Gustafsson L.

APMIS. 2009 Sep;117(9):660-71. doi: 10.1111/j.1600-0463.2009.02521.x.

PMID:
19703126
18.

Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age.

Kilpi TM, Silfverdal SA, Nilsson L, Syrjänen R, Belloni C, Desole M, Triban C, Storsaeter J, Soila M, Jacquet JM.

Hum Vaccin. 2009 Jan-Feb;5(1):18-25. Epub 2009 Jan 2.

PMID:
18690013
19.

Changes in seroprevalence to four herpesviruses over 30 years in Swedish children aged 9-12 years.

Svahn A, Berggren J, Parke A, Storsaeter J, Thorstensson R, Linde A.

J Clin Virol. 2006 Oct;37(2):118-23. Epub 2006 Sep 12.

PMID:
16971177
21.

Is there a need for a new generation of vaccines against pertussis?

Storsaeter J, Wolter J.

Expert Opin Emerg Drugs. 2006 May;11(2):195-205. Review.

PMID:
16634696
22.

Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose.

Hallander HO, Gustafsson L, Ljungman M, Storsaeter J.

Vaccine. 2005 Nov 16;23(46-47):5359-64. Epub 2005 Jul 1.

PMID:
16051400
23.

A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age.

Nilsson L, Faldella G, Jacquet JM, Storsaeter J, Silfverdal SA, Ekholm L.

Scand J Infect Dis. 2005;37(3):221-9.

PMID:
15849057
24.

Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.

Parment PA, Svahn A, Rudén U, Bråkenhielm G, Storsaeter J, Akesson L, Linde A.

Scand J Infect Dis. 2003;35(10):736-42.

PMID:
14606613
25.
26.

[Alone and isolated].

Storsaeter J.

Lakartidningen. 2003 May 28;100(22):2002. Swedish. No abstract available.

PMID:
12833738
27.

Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine.

Olin P, Gustafsson L, Barreto L, Hessel L, Mast TC, Rie AV, Bogaerts H, Storsaeter J.

Vaccine. 2003 May 16;21(17-18):2015-21.

PMID:
12706691
28.

Calibrated serological techniques demonstrate significant different serum response rates to an oral killed cholera vaccine between Swedish and Nicaraguan children.

Hallander HO, Paniagua M, Espinoza F, Askelöf P, Corrales E, Ringman M, Storsaeter J.

Vaccine. 2002 Nov 22;21(1-2):138-45.

PMID:
12443672
29.

How to make sense of pertussis immunogenicity data.

Olin P, Hallander HO, Gustafsson L, Reizenstein E, Storsaeter J.

Clin Infect Dis. 2001 Dec 15;33 Suppl 4:S288-91. Review.

PMID:
11709761
30.

[Should school children receive pertussis vaccine?].

Sandbu S, Nøkleby H, Helland OS, Feiring B, Bondevik M, Sundelin F, Storsaeter J.

Tidsskr Nor Laegeforen. 2001 May 10;121(12):1464-8. Norwegian.

31.

Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster.

Tiru M, Hallander HO, Gustafsson L, Storsaeter J, Olin P.

Vaccine. 2000 Apr 28;18(21):2295-306.

PMID:
10717350
32.

[A new vaccination campaign for better protection against whooping cough of infants].

Blennow M, Gothefors L, Storsaeter J.

Lakartidningen. 1999 Jul 28;96(30-31):3320. Swedish. No abstract available.

PMID:
10459235
33.

Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.

Storsaeter J, Hallander HO, Gustafsson L, Olin P.

Vaccine. 1998 Dec;16(20):1907-16.

PMID:
9796042
34.

Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children.

Ryan M, Murphy G, Ryan E, Nilsson L, Shackley F, Gothefors L, Oymar K, Miller E, Storsaeter J, Mills KH.

Immunology. 1998 Jan;93(1):1-10.

35.

Catch-up primary vaccination with acellular pertussis vaccines in 3-4-year-old children--reactogenicity and serological response.

Wärngård O, Nilsson L, Fåhraeus C, Gustafsson L, Hallander HO, Olin P, Storsaeter J.

Vaccine. 1998 Mar;16(5):480-4.

PMID:
9491502
36.

Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells.

Ryan M, Murphy G, Gothefors L, Nilsson L, Storsaeter J, Mills KH.

J Infect Dis. 1997 May;175(5):1246-50.

PMID:
9129097
38.

Absolute efficacy of acellular pertussis vaccines in household settings.

Storsaeter J, Gustafsson L.

Dev Biol Stand. 1997;89:153-9.

PMID:
9272345
39.

Hypotonic hyporesponsive episodes in eight pertussis vaccine studies.

Heijbel H, Ciofi degli Atti M, Harzer E, Liese J, Preziosi MP, Rasmussen F, Schmitt HJ, Storsaeter J, Taranger J, Uberall M, Tozzi AE.

Dev Biol Stand. 1997;89:101-3. No abstract available.

PMID:
9272338
40.

[2 vaccine dosages for basic prevention of whooping cough in children over 2 years of age?].

Gothefors L, Storsaeter J.

Lakartidningen. 1996 Jul 10;93(28-29):2564. Swedish. No abstract available.

PMID:
8801406
41.

Lack of association between pertussis vaccination and symptoms of asthma and allergy.

Nilsson L, Kjellman NI, Storsaeter J, Gustafsson L, Olin P.

JAMA. 1996 Mar 13;275(10):760. No abstract available.

PMID:
8598591
42.

A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.

Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J.

N Engl J Med. 1996 Feb 8;334(6):349-55. Erratum in: N Engl J Med 1996 May 2;334(18):1207.

43.

Pertussis antibodies, protection, and vaccine efficacy after household exposure.

Storsaeter J, Blackwelder WC, Hallander HO.

Am J Dis Child. 1992 Feb;146(2):167-72.

PMID:
1733145
44.
45.

Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions.

Blackwelder WC, Storsaeter J, Olin P, Hallander HO.

Am J Dis Child. 1991 Nov;145(11):1285-9.

PMID:
1951222
46.

Evaluation of serology and nasopharyngeal cultures for diagnosis of pertussis in a vaccine efficacy trial.

Hallander HO, Storsaeter J, Möllby R.

J Infect Dis. 1991 May;163(5):1046-54.

PMID:
2019753
47.

Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial.

Storsaeter J, Hallander H, Farrington CP, Olin P, Möllby R, Miller E.

Vaccine. 1990 Oct;8(5):457-61.

PMID:
2251872
48.

The efficacy of acellular pertussis vaccine.

Olin P, Storsaeter J, Romanus V.

JAMA. 1989 Jan 27;261(4):560. No abstract available. Erratum in: JAMA 1989 Jul 7;262(1):33.

PMID:
2909797
49.

Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden.

Storsaeter J, Olin P, Renemar B, Lagergård T, Norberg R, Romanus V, Tiru M.

Pediatr Infect Dis J. 1988 Sep;7(9):637-45.

PMID:
3050858
50.

[Protective effect of 2 acellular pertussis vaccines in a double-blind placebo controlled clinical trial].

Kallings LO, Olin P, Storsaeter J.

Lakartidningen. 1988 Jun 1;85(22):1994-6. Swedish. No abstract available.

PMID:
3287070

Supplemental Content

Loading ...
Support Center